In terms of alteration types, ITGA10 had high amplification rates in hepatocellular carcinoma (LIHC, 9.7%), BRCA (9.2%), and bladder urothelial carcinoma (BLCA, 9.0%), whereas it predominantly mutated in SKCM (7.8%). This evidence concerns the gene ITGA10 and hepatocellular carcinoma.